Találati lista | Tudóstér

001-es BibID:	BIBFORM117716
035-os BibID:	(cikkazonosító)e079309 (WoS)001177385500001 (Scopus)85185348688
Első szerző:	Torp, Nikolaj
Cím:	Personalised human albumin in patients with cirrhosis and ascites : design and rationale for the ALB-TRIAL - a study protocol of a randomised clinical biomarker validation trial / Nikolaj Torp, Mads Israelsen, Minneke Coenraad, Maria Papp, Debbie L. Shawcross, Marko Korenjak, Paolo Angeli, Wim Laleman, Adria Juanola, Pere Gines, Jonel Trebicka, Alexander Krag, MINCROB-PREDICT Consortium
Dátum:	2024
ISSN:	2044-6055
Megjegyzések:	Abstract Introduction; Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine approach with biomarkers to predict human albumin treatment response, so called predictive biomarkers, could make this a viable treatment option in patients with cirrhosis and ascites. Methods and analysis; ALB-TRIAL is a multinational, double-blind, placebo-controlled randomised controlled rial. We aim to validate a predictive biomarker, consisting of a panel of circulating metabolites, to predict the treatment response to human albumin in patients with cirrhosis and ascites. All enrolled patients are stratified into a high- or low expected effect stratum of human albumin based on the biomarker outcome. After stratification, patients in each group are randomised into either active treatment (20% human albumin) or corresponding placebo (0.9% NaCl) every 10th day for 6 months. The primary outcome is the cumulative number of liver-related events (composite of decompensation episodes, transjugular intrahepatic shunt insertion, liver transplantation and death). Key secondary outcomes include time-to-event analysis of primary outcome components, an analysis of the total healthcare burden and a health economic analysis. Ethics and dissemination; The trial obtained ethical- and regulatory approval in Denmark, Germany, the Netherlands, Belgium, Hungary and Spain through the Clinical Trials Information System (CTIS) from 13 February 2023, while United Kingdom approvals from the Health Regulatory Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) are pending. Findings will be published in peer-reviewed journals, presented at conferences, communicated to relevant stakeholders and in the public registry of CTIS, following trial completion.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk cirrhosis biomarker RCT validation ascites albumin personalised medicine protocol
Megjelenés:	BMJ Open. - 14 : 2 (2024), p. 1-8. -
További szerzők:	Israelsen, Mads Coenraad, Minneke Papp Mária (1975-) (belgyógyász, gasztroenterológus) Shawcross, Debbie L. Korenjak, Marko Angeli, Paolo Laleman, Wim Juanola, Adria Ginès, Pere Trebica, Jonel Krag, Aleksander MINCROB-PREDICT Consortium
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: